Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

  • Holly L. Geyer
    Division of Hospital Internal Medicine and
  • Robyn M. Scherber
    Division of Hospital Internal Medicine and
  • Amylou C. Dueck
    Section of Biostatistics, Mayo Clinic, Scottsdale, AZ;
  • Jean-Jacques Kiladjian
    Clinical Investigation Center, Hospital Saint-Louis, Paris, France;
  • Zhijian Xiao
    Myelodysplastic Syndrome and Myeloproliferative Neoplasia Centre, Institute of Hematology and Blood Diseases Hospital and
  • Stefanie Slot
    Department of Hematology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands;
  • Sonja Zweegman
    Department of Hematology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands;
  • Federico Sackmann
    Fundaleu, Buenos Aires, Argentina;
  • Ana Kerguelen Fuentes
    Department of Haematology, University Hospital La Paz, Madrid, Spain;
  • Dolores Hernández-Maraver
    Department of Haematology, University Hospital La Paz, Madrid, Spain;
  • Konstanze Döhner
    Department of Internal Medicine III, University Hospital of Ulm, Germany;
  • Claire N. Harrison
    Department of Haematology, Guy’s and St. Thomas National Health Service Foundation Trust, London, United Kingdom;
  • Deepti Radia
    Department of Haematology, Guy’s and St. Thomas National Health Service Foundation Trust, London, United Kingdom;
  • Pablo Muxi
    Unidadde Hematología, Hospital Británico, Montevideo, Uruguay;
  • Carlos Besses
    Hematology Department, Hospital del Mar, Barcelona, Spain;
  • Francisco Cervantes
    Hematology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Spain;
  • Peter L. Johansson
    Internal Medicine, Nephro-Urology Hospital Organization, Uddevalla, Sweden;
  • Bjorn Andreasson
    Internal Medicine, Nephro-Urology Hospital Organization, Uddevalla, Sweden;
  • Alessandro Rambaldi
    Unit of Hematology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy;
  • Tiziano Barbui
    Unit of Hematology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy;
  • Alessandro M. Vannucchi
    Hematology Division of Hematology, Ospedale di Circolo, Varese, Italy;
  • Francesco Passamonti
    Department of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy;
  • Jan Samuelsson
    Department of Internal Medicine, Stockholm South Hospital, Stockholm, Sweden;
  • Gunnar Birgegard
    Department of Hematology, University Hospital, Uppsala, Sweden; and
  • Ruben A. Mesa
    Department of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ

抄録

<jats:title>Key Points</jats:title> <jats:p>Distinct clusters exist within polycythemia vera, essential thrombocythemia, and myelofibrosis. Clusters are not direct surrogates for current prognostic scores.</jats:p>

収録刊行物

  • Blood

    Blood 123 (24), 3803-3810, 2014-06-12

    American Society of Hematology

被引用文献 (3)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ